OFFICE OF REGULATORY AFFAIRS DECENTRALIZATION PLAN TO REDUCE HQ STAFF
OFFICE OF REGULATORY AFFAIRS DECENTRALIZATION PLAN TO REDUCE HQ STAFF by 10%-15% per year over five years will require "moving more and more activities out to the field organizations," FDA Deputy Associate Commissioner for Regulatory Affairs Gary Dykstra told the PDA/FDA Joint Conference in Bethesda, Md, Sept, 20, "We have to do the same amount of work with less people" because of budget constraints and staff reductions mandated as part of Vice- President Gore's National Performance Review report, Dykstra explained.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth